- The European Medicines Agency grants PRIME status for Roche's (OTCQX:RHHBY) risdiplam for the treatment of spinal muscular atrophy (SMA).
- PRIME, akin to Breakthrough Therapy status in the U.S., provides for more intensive guidance on development and accelerated review of the market application.
- The company is developing the orally administered survival motor neuron-2 gene splicing modifier with the SMA Foundation and PTC Therapeutics (NASDAQ:PTCT).
- SMA-related tickers: (NASDAQ:BIIB)(NASDAQ:IONS)(NASDAQ:SRRK)(NYSE:NVS)(NASDAQ:CYTK)